FDA Oncologic Drug Committee Agrees That “Kitty Fight” With NCI Should Be Negotiated
In Brief: NCI Tells Cooperative Groups To Submit applications For Extra Multimodality Funds
FDA Delays NDA On BCNU, But New Drug Seminar Still Scheduled
Proposed Guidelines For Clinical Tests Of Oncologic Drugs
UCLA, NYU, Ohio States Must Wait Longer For Comprehensive Status
Contact Planned To Encourage Insurers To Reimburse For Cancer Screening
Rosemond Asks Ban On High Tar, Nicotine Cigarettes
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members









